Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. - Test2 - elhamkhani - TriplyDB

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.

http://www.wikidata.org/entity/Q33863459

about

Neural correlates of the LSD experience revealed by multimodal neuroimaging Lysergic acid diethylamide: a drug of 'use'?Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years Recent advances in the neuropsychopharmacology of serotonergic hallucinogens d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology.Psychedelics LSD enhances the emotional response to music.Modern Clinical Research on LSD.Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.Alterations of consciousness and mystical-type experiences after acute LSD in humans.Pharmacokinetics and Concentration-Effect Relationship of Oral LSD in Humans.Psychedelic medicine: a re-emerging therapeutic paradigm.Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)Clinical applications of hallucinogens: A review.Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.LSD Acutely Impairs Fear Recognition and Enhances Emotional Empathy and Sociality Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial.Peak experiences and the afterglow phenomenon: when and how do therapeutic effects of hallucinogens depend on psychedelic experiences?LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark.Serotonin and brain function: a tale of two receptors The detection and prevention of unintentional consumption of DOx and 25x-NBOMe at Portugal's Boom Festival.The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.Potential Therapeutic Effects of Psilocybin.Development and validation of an LC-MS/MS method to quantify lysergic acid diethylamide (LSD), iso-LSD, 2-oxo-3-hydroxy-LSD, and nor-LSD and identify novel metabolites in plasma samples in a controlled clinical trial.Therapeutic Applications of Classic Hallucinogens.Antidepressive and anxiolytic effects of ayahuasca: a systematic literature review of animal and human studies.Safety pharmacology of acute MDMA administration in healthy subjects.The current state of research on ayahuasca: A systematic review of human studies assessing psychiatric symptoms, neuropsychological functioning, and neuroimaging.Decreased mental time travel to the past correlates with default-mode network disintegration under lysergic acid diethylamide.Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects.Psychedelics as Medicines: An Emerging New Paradigm.Phenomenology, Structure, and Dynamic of Psychedelic States.Back to the future: a return to psychedelic treatment models for addiction.Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.Development and validation of a rapid turboflow LC-MS/MS method for the quantification of LSD and 2-oxo-3-hydroxy LSD in serum and urine samples of emergency toxicological cases.Does psychedelic drug use reduce risk of suicidality? Evidence from a longitudinal community-based cohort of marginalised women in a Canadian setting.Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms.Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.

P2860

Q24174843-D4DC4CA6-80A6-40CC-B47F-1124C17E7333 Q26746133-8AD03797-0534-4605-A77B-7A74A4DEB254 Q26746137-0FD8E0B3-7FF2-4DDE-AA9B-C562895B7032 Q27027381-61A50AF3-E899-4E1C-8B26-104E489D4C22 Q28067851-24339EF3-D944-439A-8643-56C30025A296 Q30359998-81B6FE4E-6654-4876-9ADC-D00BDAE3CA04 Q30377709-0569B72E-4D11-44BD-9FA1-E68D39CAD6F3 Q30401421-46CD1D39-7C00-4065-B033-540BBB73C929 Q30843010-4330B8FC-EF8B-4D22-862C-E5733A2C1D69 Q30847957-AA30AB95-FF6D-4A8A-B34E-7AF13D149391 Q34482174-F813E80E-A1AB-4158-8F7C-4238B3AD5E18 Q34493217-D3AA4F81-E21D-40CA-AFDF-748946689820 Q34497649-0017450E-BFEA-4082-B442-5893129CCF06 Q34535259-35DD8401-3541-4661-9EEC-E0DC41043287 Q34674320-8BB60E4B-6C68-408B-BCC0-DFE6C8A035F6 Q35126018-EF5EDE86-BD9E-42C5-969E-582BD82CA473 Q37262799-C0FD3D33-23A6-4CCE-9CD1-BC73C6A7B062 Q37722650-95EE16E4-2B97-4D41-B760-E2D0BD9FAAF0 Q38351502-153BD3AC-9B95-4BEB-82E5-A1FFC0460AB6 Q38373370-99840B49-A287-4DE7-AFE1-386209CA6C90 Q38600048-DF3B6301-B695-4D67-A8EC-3883DF5B7C3A Q38668682-EEFA4658-E6BF-4A8D-9388-BE92A9B29F9C Q38690821-822FEB4F-F29C-4437-A881-BB832A97DCF1 Q38741517-781C4BE4-A791-4362-A5B1-5AFD9C9AD354 Q38761743-45A032A8-1FF6-4785-9482-3F74DDB2017D Q38781678-D5FD6363-A383-4821-AAAF-ED921C2ABD02 Q38816768-F6983AE5-F823-41BA-985E-B3657503D3CC Q38819567-EF484E35-70CA-4ED2-8844-A30BDB845D82 Q38861685-8D7FD6D8-F53F-4196-8F51-98044ABCF7E4 Q38894887-05968B72-D82C-4AFE-B109-40DB8A9E82C3 Q38961114-6FDC71BE-35C8-4273-8BD0-72ACF7014D81 Q39055247-A7A2E6F4-C843-47DE-B0A2-14618BB4573F Q39057372-FB738382-0C23-4189-A62D-D77689C1B9FF Q39123721-0BF8797A-914D-4336-8203-51AD035D7F0E Q39548034-A8B6969E-29F4-49DD-B3F2-669BC84A91F7 Q41586201-51DE2370-CD1E-4AEF-9F40-19157E895174 Q41647007-DFB91526-7066-4914-8909-3D2F051B0BF2 Q41932270-8431B6F0-E5DB-4C9E-AE1A-0901BE890224 Q42377130-8C9D58BD-32D6-4949-B9A1-05A96958E000 Q47577495-EBA900BB-116C-4890-9CC7-A1F42259270A

P2860

Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases.

http://www.wikidata.org/entity/Q33863459

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

name

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@ast

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@en

type

label

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@ast

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@en

prefLabel

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@ast

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@en

P1433

Q33863459-04601892-8112-4908-9C75-87138811D3C7

P1476

Q33863459-764698AC-F175-4574-BAEF-D2DE83EE759B

P2093

Q33863459-022FED63-3946-43C7-A119-0BEAA18BAAEF

Q33863459-0AEDFD37-F4E5-4D96-BFFC-48AF634DE7A4

Q33863459-1780D6BF-1B4E-4D94-BD48-EC8E03C6C06A

Q33863459-84029652-2F1D-412A-A65D-EE8C418AA561

Q33863459-BB9FFDD2-0A9A-426C-AC7F-5A9465D6FF97

Q33863459-D8BC3E42-0632-494C-ACB1-4D248E7ACA63

Q33863459-F0A3FFB8-2426-404E-8994-FB4AE86B75BD

P2860

Q33863459-044116D5-CF58-4FC8-9083-8924DA5F762C

Q33863459-08655319-2617-4C11-9626-4FFA7BCE1F08

Q33863459-15F2D084-5BED-4A77-8C97-66277405ACC4

Q33863459-2117C9C9-761D-4B0B-8B80-2C2E6DF0F85E

Q33863459-24D99287-E8D0-45AA-BA2A-4AC6D25D32D5

Q33863459-28B0757D-D4AF-42F4-BDA5-6AD71EACAB73

Q33863459-296D1FC6-8188-4DF3-9775-4435754771BC

Q33863459-2A24D266-AAFC-46AE-AECC-0D6635FFDEFB

Q33863459-3A60A023-402B-4CAA-B417-6F5483094CDD

Q33863459-5D9E80D8-9118-417E-99BE-F1C701BFA17F

P304

Q33863459-18141B7E-DB37-4D57-8BA8-77784BC49AB7

P31

Q33863459-64415307-F05D-4491-970B-9D9EE6FDC5A8

P356

Q33863459-5D5B2A98-E9C1-4B95-8285-E5E422F5DF9B

P407

Q33863459-7E5D8B47-91CC-4925-B957-445B5774C5B0

P433

Q33863459-9EB607D8-E0AB-467C-BF72-5DCCD7F4FFDB

P478

Q33863459-5ABC3B50-9A23-46DA-ACCB-D8FD11394DFA

P577

Q33863459-1F442FA3-002B-4E5E-A010-AC05F32F4F1C

P5875

Q33863459-A6530D0C-5B9B-402E-ABEE-DF42E01A4E82

P698

Q33863459-80AB4A4C-273D-4C24-8176-B788423A7C43

P921

Q33863459-EFD94612-4500-47F6-87B7-5DA8511C53D2

P932

Q33863459-F41899C7-7750-41BF-8E39-81093F59B9E8

P356

NMD.0000000000000113

P1433

Journal of Nervous and Mental Disease

P1476

Safety and efficacy of lysergi ...... ith life-threatening diseases.

@en

P2093

Berra Yazar-Klosinski

http://www.w3.org/2001/XMLSchema#string

Dominique Holstein

http://www.w3.org/2001/XMLSchema#string

Peter Gasser

http://www.w3.org/2001/XMLSchema#string

Rick Doblin

http://www.w3.org/2001/XMLSchema#string

Rudolf Brenneisen

http://www.w3.org/2001/XMLSchema#string

Torsten Passie

http://www.w3.org/2001/XMLSchema#string

Yvonne Michel

http://www.w3.org/2001/XMLSchema#string

P2860

The pharmacology of lysergic acid diethylamide: a review.

Long Lasting Effects of LSD on Normals

Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness

Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Differential item functioning (DIF) in the EORTC QLQ-C30: a comparison of baseline, on-treatment and off-treatment data.

Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer.

How LSD originated.

P304

513-520

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/NMD.0000000000000113

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260525854

http://www.w3.org/2001/XMLSchema#string

P698

24594678

http://www.w3.org/2001/XMLSchema#string

P921

Acid lisergic dietilamid

P932

4086777

http://www.w3.org/2001/XMLSchema#string